Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx, Seth Taylor, Kevin Croker, Shane Weber, Agilent Technologies, Brandeis University, Nanosphere, Nanogen, Duke University

Premium

Zyomyx received US Patent No. 6,682,942, “Microdevices for screening biomolecules.” The patent covers a system for the parallel, in vitro screening of biomolecular activity using miniaturized microfabricated devices. In this system, the biomolecules immobilized on the surface of the devices include proteins, polypeptides, polynucleotides, polysaccharides, phospholipids, and related unnatural polymers of biological relevance. Each of the reactive sites comprises a substrate, an organic thin film chemisorbed or physisorbed on a portion of a surface of the substrate, and a biological moiety immobilized on the organic thin film, wherein each of the reactive sites may independently react with a component of the fluid sample and are separated from each other by a region of the substrate that is free of organic thin film. In a particularly preferred embodiment of the device, each of the reactive sites on the device of the invention is in a microchannel oriented parallel to microchannels of other reactive sites on the device, where the microchannels are microfabricated into or onto the substrate.


Seth Taylor of Cambridge, Mass.; Kevin Croker of Cheshire, Conn.; and Shane Weber of Woodbridge, Conn.; received US Patent No. 6,682,893, “Gel pad arrays and methods and systems for making them.” The patent covers gel pads and gel pad arrays, and methods for making and using them. The inventors claim the arrays can be used for sequencing by hybridization, and for cell-based assays. The invention features multi-layered gel pad constructs and methods of making and using them.


Agilent Technologies received US Patent No. 6,682,702, “Apparatus and method for simultaneously conducting multiple chemical reactions.” The patent covers a method and a technology for simultaneously conducting multiple chemical reactions that combine a test sample with a chemical reactant in closed reaction chambers to produce reaction products. The method comprises assembling a plate having the test sample in spatially arranged wells with a microarray of similarly arranged surface-bound chemical reactants to form a sealed apparatus having closed reaction chambers. The seal may be accomplished with a flexible array substrate or a flexible gasket, and one or more mechanical clamps, external fluid pressure, radiation, heat, vacuum and an adhesive. The sealed apparatus can be subjected to various reaction conditions, such as intense mechanical agitation and a controlled temperature environment. A kit comprises one or more of the elements of the apparatus.


Brandeis University received US Patent No. 6,680,377, “Nucleic acid-based detection.” The patent covers a system for simultaneously detecting the presence and quantity of one or more different compounds in a sample using aptamer beacons. Aptamer beacons are oligonucleotides that have a region that can bind to a non-nucleotide target molecule, such as a protein, a steroid, or an inorganic molecule. New aptamer beacons can be used in solution-based and solid array-based systems. The aptamer beacons can be attached to solid supports, e.g., at different predetermined points in two-dimensional arrays. The invention includes devices, methods, and computer software for carrying out the methods.


Nanosphere of Northbrook, Ill., received US Patent No. 6,682,895, “Nanoparticles having oligonucleotides attached thereto and uses therefore.” The patent covers methods for detecting a nucleic acid by contact with one or more types of nanoparticles having oligonucleotides attached. A detectable change (preferably a color change) is brought about as a result of the hybridization of the oligonucleotides on the nanoparticles to the nucleic acid. The patent also covers compositions and kits comprising particles. The invention also provides methods of synthesizing unique nanoparticle-oligonucleotide conjugates, the conjugates produced by the methods, and methods of using the conjugates. In addition, the invention provides nanomaterials and nanostructures comprising nanoparticles and methods of nanofabrication utilizing nanoparticles. Finally, the invention provides a method of separating a selected nucleic acid from other nucleic acids.


Nanogen received US Patent No. 6,682,936, “Addressable biologic electrode array.” The patent covers a biologic electrode array assembly formed on an integrated circuit chip that includes an array of electrodes coupled to metal oxide semiconductor switches.


Duke University received US Patent No. 6,682,927, “Methods and apparatus for the high throughput detection of binding interactions in vivo.” The patent covers an apparatus for screening for translocation of a first protein of interest in vivo in a plurality of cells comprising: (a) a thin unitary total internal reflection member having a surface portion; (b) a cell contacted to the surface by the plasma membrane of the cell, with the cell containing the first protein of interest, which has a fluorescent group conjugated to it; (c) a light source; (d) a coupling for attaching the light source; and (e) a light detector configured to detect emitted light from the cells, which indicates the translocation of the protein.

 

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.